Lonza vs Samsung Biologics: CDMO Comparison
How does Lonza compare to Samsung Biologics for mRNA/LNP manufacturing?
Side-by-side comparison of Lonza and Samsung Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Lonza has FDA inspections on record (2); Samsung Biologics does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Lonza holds 3 active EMA GMP certificates; Samsung Biologics does not appear in EudraGMDP.
- Lonza maintains 5 MHRA / UK GMP certificates; Samsung Biologics does not.
- Composite Signal Score: Lonza 76/100 vs Samsung Biologics 62/100 — a 14-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both Lonza and Samsung Biologics qualify as mRNA/LNP manufacturers; Lonza carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both Lonza and Samsung Biologics qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: Lonza vs Samsung Biologics
How does Lonza compare to Samsung Biologics for mRNA/LNP manufacturing?
On CDMO Signal's composite Signal Score, Lonza is 76/100 and Samsung Biologics is 62/100; Lonza has 2 FDA inspections on record vs 0 for Samsung Biologics; European coverage is 8 active EMA+MHRA certificates for Lonza vs 0 for Samsung Biologics. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Lonza or Samsung Biologics?
Both Lonza and Samsung Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Lonza has 2 FDA inspections on record; Samsung Biologics has 0.
How do Lonza and Samsung Biologics compare on European GMP coverage?
Lonza holds 3 active EMA GMP certificates and 5 MHRA / UK certificates. Samsung Biologics holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Lonza or Samsung Biologics?
Lonza is matched to 1 ClinicalTrials.gov record as a manufacturing partner; Samsung Biologics is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for mRNA/LNP manufacturing — Lonza or Samsung Biologics?
Both Lonza and Samsung Biologics are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →